Drug prices and value for money: The Australian Pharmaceutical Benefits Scheme

JAMA

Volumn 294, Issue 20, 2005, Pages 2630-2632

  Henry, David A ^a,c   Hill, Suzanne R ^a   Harris, Anthony ^b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c NEWCASTLE MATER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUSTRALIA; BUDGET; COST EFFECTIVENESS ANALYSIS; DRUG DOSE; DRUG INDUSTRY; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH PROGRAM; MEDICARE; NOTE; POLITICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

EID: 28144440769     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.20.2630     Document Type: Note

References (26)

1. Pearson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA. 2005;294:2618-2622.
2. National Institute for Health and Clinical Excellence Web site. Available at: http://www.nice.org.uk. Accessed October 13, 2005.
3. Canadian Coordinating Office for Health Technology Assessment Web site. Available at: https://www.ccohta.ca. Accessed October 13, 2005.
4. Instituto de Salud Carlos III Web site. Available at: http://www.isciii.es. Accessed October 13, 2005.
5. Hill SR, Stevens A, Henry DA. A review of the use of evidence in the PBS. In: Informing Judgement: Case Studies of Health Policy and Research in Six Countries. New York, NY: Milbank Memorial Fund; 2001.
6. Dutch Guidelines for Pharmacoeconomic Research. Available at: http://www.ispor.org/PEguidelines/source/PE_guidelines_english_Netherlands.pdf. Accessed October 13, 2005.
7. Laupacis A. Incorporating economic evaluations into decision-making: the Ontario experience. Med Care. 2005;43(7 suppl):15-19.
8. Medicare Prescription Drug Improvement and Modernization Act of 2003. Pub L 108-173 (2003). Available at: http://www.cms.hhs.gov/mmu/HR1/HR1.pdf. Accessed October 13, 2005.
9. Birkett DJ, Mitchell AS, McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Aff (Millwood). 2001;20:104-114.
10. Medical Services Advisory Committee Web site. Available at: http://www7.health.gov.au/msac. Accessed October 13, 2005.
11. Weekes LM, Mackson JM, Fitzgerald M, Phillips SR. National Prescribing Service: creating an implementation arm for national medicines policy. Br J Clin Pharmacol. 2005;59:112-116.
12. Therapeutic Guidelines Ltd Web site. Available at: http://www.tg.com.au. Accessed October 13, 2005.
13. Henry DA, Birkett DJ. Changes to the Pharmaceutical Benefits Advisory Committee. Med J Aust. 2001;174:209-210.
14. Cookson R, McDaid D, Maynard A. Wrong SIGN, NICE mess: is national guidance distorting allocation of resources? BMJ. 2001;323:743-745.
15. Poole-Wilson PA. NICE: guessing is not guidance. Heart. 2002;87:510-512.
16. Maynard A, Bloor K, Freemantle N. Challenges for the National Institute for Clinical Excellence. BMJ. 2004;329:227-229.
17. Whitty P, Gilbody S. NICE, but will they help people with depression? the new National Institute for Clinical Excellence depression guidelines. Br J Psychiatry. 2005;186:177-178.
18. US Department of Commerce. Pharmaceutical Price Controls in OECD Countries: Implications for U.S. Consumers, Pricing, Research and Development, and Innovation. December 2004. Available at: http://www.ita.doc.gov/td/chemicals /drugpricingstudy.pdf. Accessed October 13, 2005.
19. Harvey KJ, Faunce TA, Lokuge B, Drahos P. Will the Australia-United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme? Med J Aust. 2004;181:256-259.
20. Department of Health and Ageing Web site. Available at: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ PBS+Publications-1. Accessed October 10, 2005.
21. Harris AH. Uncertainty, economics and the decision to fund drugs in Australia. Presented at: International Health Economics Association 5th World Congress; July 2005; Barcelona, Spain.
22. Hill S, Mitchell AS, Henry DA. Problems with pharmacoeconomic analyses. JAMA. 2000;283:2116-2121.
23. Richardson J, McKie J. The Rule of Rescue. Melbourne, Australia: Centre for Health Program Evaluation, Monash University; 2004. Working paper 112.
24. Lu CY, Williams K, Day R, March L, Sansom L, Bertouch J. Access to high cost drugs in Australia. BMJ. 2004;329:415-416.
25. Birch S, Gafni A. The "NICE" approach to technology assessment: an economics perspective. Health Care Manag Sci. 2004;7:35-41.
26. Sheldon TA, Cullum N, Dawson D, et al. What's the evidence that NICE guidance has been implemented? BMJ. 2004;329:999-1007.